Ian Charles - Feb 29, 2024 Form 4 Insider Report for Glimpse Group, Inc. (VRAR)

Role
Director
Signature
/s/ Ian Charles
Stock symbol
VRAR
Transactions as of
Feb 29, 2024
Transactions value $
$0
Form type
4
Date filed
3/5/2024, 10:12 AM
Previous filing
Jun 1, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRAR Stock Option (Right to Purchase) Disposed to Issuer $0 -30.6K -100% $0.00* 0 Feb 29, 2024 Common Stock 30.6K Direct F1
transaction VRAR Stock Option (Right to Purchase) Award $0 +20.5K +85.31% $0.00 44.5K Mar 1, 2024 Common Stock 20.5K $2.50 Direct F2
transaction VRAR Stock Option (Right to Purchase) Award $0 +24K +117.22% $0.00 44.5K Mar 1, 2024 Common Stock 24K $2.50 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the forfeiture, by Mr. Charles, of fully vested options to purchase an aggregate of 30,560 shares of the issuer's common stock granted under the issuer's 2016 equity incentive plan, as amended (the "2016 Plan"), consisting of (i) options to purchase 10,560 shares of the issuer's common stock granted to Mr. Charles on January 13, 2022 with an exercise price of $10.09 per share, and (ii) options to purchase 20,000 shares of the issuer's common stock granted to Mr. Charles on February 27, 2023 with an exercise price of $5.00 per share. The foregoing options were to expire 10 years from their respective grant dates.
F2 Mr. Charles was granted options to purchase 20,475 shares of the issuer's common stock under the 2016 Plan on March 1, 2023, which options became exercisable upon grant with an exercise price of $2.50 per share. These options are set to expire seven years from grant date.
F3 Represents options to purchase 24,000 shares of the issuer's common stock granted to Mr. Charles on March 1, 2024, as director compensation for calendar year 2024. The options vest monthly in arrears, retroactive to January 1, 2024 with an exercise price of $2.50 per share. These options are set to expire 10 years from grant date.